The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).
 
Maria Gonzalez
No Relationships to Disclose
 
Angela M. Hong
Speakers' Bureau - BMS Brazil
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec
 
Wei Wang
No Relationships to Disclose
 
Serigne Lo
No Relationships to Disclose
 
Michael Paul Brown
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pharmaust (Inst); Roche (Inst); Zucero Therapeutics (Inst)
 
Matthew C. Foote
No Relationships to Disclose
 
Mark B. Pinkham
Employment - Icon Cancer Care
Honoraria - MSD
Travel, Accommodations, Expenses - MSD
 
Hien Le
No Relationships to Disclose
 
Daniel E. Roos
No Relationships to Disclose
 
Monica Osorio
No Relationships to Disclose
 
Neda Haghighi
Stock and Other Ownership Interests - Australian Clinical Laboratories (I)
Honoraria - ICON cancer care
Consulting or Advisory Role - ICON cancer care
 
David Kok
No Relationships to Disclose
 
Michael A. Postow
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis
Research Funding - Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
 
Grant A. McArthur
Research Funding - Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); MSD (Inst); MSD Oncology (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)